FindTrial
Sign In

Utility of CB-NAAT (a diagnostic test) in diagnosing cases of skin tuberculosis.

CB-NAAT, Its clinical utility in diagnosing cases of cutaneous tuberculosis and assessing rifampicin resistance.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/02/017549
Enrollment
35
Registered
2019-02-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: not applicable: not applicable Control Intervention1: NA: NA

Sponsors

King Georges Medical University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (a) Patients clinically diagnosed as cutaneous TB and who give consent to participate in the study

Exclusion criteria

Exclusion criteria: (a) Who have taken ATT in last one year (b) Contra-indication for biopsy or FNAC like bleeding and clotting disorders (c) Patients with severe debilitating and chronic illness like Hepatitis B,C, malignancy, uncontrolled diabetes etc (d) Not willing to participate in study

Design outcomes

Primary

MeasureTime frame
To assess and compare the efficacy of CBNAAT, culture and histopathological examination (including staining for AFB) in diagnosing cases of cutaneous TB.Timepoint: 1.5 years—

Secondary

MeasureTime frame
Assessment and comparison of Rifampicin resistance results shown by CBNAAT and DST (for cases that show culture growth).Timepoint: 1.5 years—

Countries

India

Contacts

Public ContactPARUL VERMA

KING GEORGES MEDICAL UNIVERSITY

parulverma6@gmail.com7703056441

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026